Sermorelin
A growth-hormone-releasing hormone analog that stimulates the pituitary to produce GH naturally.
Also known as: GRF 1-29, Geref
Regulatory Status
Classification date: 2024-01-15
Compounding: Legal through licensed 503A/503B pharmacies
Evidence Summary
How It Works
Sermorelin binds to GHRH receptors on anterior pituitary somatotroph cells, triggering endogenous growth hormone secretion in a pulsatile, physiologic pattern. Unlike exogenous GH, it preserves the hypothalamic-pituitary feedback loop, reducing the risk of supraphysiologic GH levels. This makes it a preferred option for age-related GH decline because the body retains regulatory control over peak hormone concentrations.
Common Applications
Safety & Considerations
Generally well tolerated. Common side effects include injection-site reactions, facial flushing, and headache. Contraindicated in patients with active malignancy. Should not be used during pregnancy or breastfeeding. Periodic IGF-1 monitoring is recommended.
Available Through Our Network
This peptide is available through our partner pharmacies with a valid prescription.
Coming Soon →Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2024-01-15. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.